- Home
- SGA vs TNYA Comparison
SGA vs TNYA Comparison
Compare SGA & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- TNYA
- Stock Information
- Founded
- SGA 1986
- TNYA 2016
- Country
- SGA United States
- TNYA United States
- Employees
- SGA N/A
- TNYA N/A
- Industry
- SGA Broadcasting
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- SGA Consumer Discretionary
- TNYA Health Care
- Exchange
- SGA Nasdaq
- TNYA Nasdaq
- Market Cap
- SGA 74.2M
- TNYA 73.8M
- IPO Year
- SGA 1992
- TNYA 2021
- Fundamental
- Price
- SGA $12.25
- TNYA $0.58
- Analyst Decision
- SGA
- TNYA Strong Buy
- Analyst Count
- SGA 0
- TNYA 5
- Target Price
- SGA N/A
- TNYA $8.60
- AVG Volume (30 Days)
- SGA 6.2K
- TNYA 2.5M
- Earning Date
- SGA 08-07-2025
- TNYA 08-07-2025
- Dividend Yield
- SGA 8.24%
- TNYA N/A
- EPS Growth
- SGA N/A
- TNYA N/A
- EPS
- SGA 0.55
- TNYA N/A
- Revenue
- SGA $111,837,000.00
- TNYA N/A
- Revenue This Year
- SGA N/A
- TNYA N/A
- Revenue Next Year
- SGA $4.84
- TNYA N/A
- P/E Ratio
- SGA $22.21
- TNYA N/A
- Revenue Growth
- SGA N/A
- TNYA N/A
- 52 Week Low
- SGA $10.75
- TNYA $0.36
- 52 Week High
- SGA $16.57
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- SGA 51.40
- TNYA 53.16
- Support Level
- SGA $12.13
- TNYA $0.56
- Resistance Level
- SGA $12.80
- TNYA $0.64
- Average True Range (ATR)
- SGA 0.44
- TNYA 0.06
- MACD
- SGA -0.05
- TNYA -0.00
- Stochastic Oscillator
- SGA 54.40
- TNYA 41.37
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.